Vital KSK Holdings, Inc.
【Vital K.S.K.】2026 Fiscal Year Financial Results｜Net Sales Exceed 610 Billion Yen, Net Profit 7.36 Billion Yen
Consolidated net sales for the fiscal year ending March 2026 exceed 610 billion yen, with a net profit of 7.36 billion yen, maintaining year-over-year levels. Segment-wise, pharmaceutical wholesale is the largest, with active progress in R&D and M&A activities.
Key Figures
- Net Sales: 610,497 million yen (YoY +1.7％)
- Net Income Attributable to Owners of Parent: 7,362 million yen (YoY +0.7％)
- Equity Ratio: 36.6% (improved from previous term)
AI要約
Performance Overview
Consolidated net sales for the fiscal year ending March 2026 exceed 610 billion yen, with net profit reaching 7.36 billion yen, comparable to the previous year. The company has been performing steadily mainly in drug wholesale and pharmacy business, actively promoting new drugs and R&D. The largest segment is wholesale, with expanded investment through R&D expenses and M&A. The financial foundation remains solid, with the equity ratio improving to 36.6%. The dividend remains at an annual 70 yen, continuing shareholder returns.
Future Outlook and Strategy
The earnings forecast for the fiscal year ending March 2027 projects net sales exceeding 620 billion yen and net profit over 7.5 billion yen, with steady growth expected. The company will respond to drug price revisions and new drug launches while promoting DX and logistics efficiency. Through R&D and M&A, it aims to strengthen its business portfolio. Capital policies such as share buybacks and shareholder returns will be continued. Based on Long-Term Vision 2035, the company aims to innovate in pharmaceutical distribution and manufacturing businesses.
Vital K.S.K. Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
